Try our Advanced Search for more refined results
Life Sciences
-
April 14, 2026
Armistice Capital Used COVID To Juice Vaxart Stock, Jury Told
Hedge fund Armistice Capital and two of its executives exploited the COVID-19 pandemic to issue press releases that falsely inflated their controlling share in pharmaceutical company Vaxart, then dumped the shares for $250 million before the bottom fell out, investors told a California federal jury at the start of trial Tuesday.
-
April 14, 2026
4th Circ. Revives Pharma Bid To Block Maryland's 340B Law
A split Fourth Circuit panel on Tuesday tossed a Maryland district court's order denying a preliminary injunction to pharmaceutical manufacturers that have challenged a state law addressing drug delivery in the federal 340B discount program, pointing to its recent ruling that West Virginia's similar statute is likely preempted.
-
April 14, 2026
States Denied Time For Talks To Settle Drug Price-Fixing Suit
A Connecticut federal judge Tuesday denied a request by dozens of U.S. states to freeze their antitrust case against generic-drug manufacturers, a pause the states argued would allow the parties to focus on settlement talks rather than pending discovery and motion deadlines.
-
April 14, 2026
Justices Told That Eli Lilly's FCA Qui Tam Challenge Too Late
A whistleblower who secured a $183 million trial win against Eli Lilly urged the U.S. Supreme Court on Tuesday to reject its constitutional challenge over his ability to sue for the federal government, arguing the drugmaker's arguments came too late.
-
April 14, 2026
Trade Group Latest To Sue Wash. Over 340B Drug Pricing Law
Pharmaceutical Research and Manufacturers of America claims a new Washington state law attempts to illegally reshape the federal 340B Drug Pricing Program and singles out participating drugmakers with burdensome regulations, according to a fresh federal lawsuit that follows similar constitutional challenges mounted by Novartis and AbbVie.
-
April 14, 2026
Vertex Sues Former Exec To Block Move To Rival
Vertex Pharmaceuticals asked a Massachusetts state court judge to bar a former executive from taking a virtually identical role at competitor Vera Therapeutics, citing a noncompete agreement he allegedly signed.
-
April 14, 2026
FDA Offers Guidance On Safety Testing For Gene-Editing Tech
The U.S. Food and Drug Administration on Tuesday issued draft guidance recommending steps drug companies should take to evaluate the safety of gene-editing technology as they seek federal approval for cutting-edge treatments aimed at genetic diseases.
-
April 14, 2026
3rd Circ. Upholds J&J Injunction Bid Loss In Biosimilar Fight
The Third Circuit on Tuesday ruled that a Johnson & Johnson subsidiary couldn't justify its bid for an order blocking Samsung Bioepis from paving the way for a Cigna unit to launch a generic version of an anti-inflammatory treatment.
-
April 14, 2026
Eli Lilly To Purchase Cooley-Led CrossBridge In $300M Deal
Venture-backed pre-clinical biotechnology firm CrossBridge Bio Inc., advised by Cooley LLP, on Tuesday announced that it has agreed to be bought by pharmaceutical giant Eli Lilly & Co. in a deal worth up to $300 million.
-
April 14, 2026
Mich. AG Says PBMs Can't Duck Drug-Pricing Suit
Two pharmacy benefit managers can't dodge an antitrust lawsuit accusing them of price-fixing reimbursement rates because Michigan has properly claimed an antitrust violation, state Attorney General Dana Nessel told a federal court, asking it to toss aside the PBMs' dismissal bid.
-
April 14, 2026
4th Circ. Won't Rehear Allergan Overcharge Suit
The Fourth Circuit on Tuesday denied a rehearing petition lodged after a panel revived a whistleblower suit accusing an Allergan Sales LLC predecessor of overcharging Medicaid.
-
April 14, 2026
Buyers Seek Final Approval Of $4.85M Bayer Benzene Deal
A class of consumers is asking a New Jersey federal court to give final approval of a $4.85 million settlement to resolve claims that Bayer US LLC's antifungal products were contaminated with benzene.
-
April 14, 2026
Avanos Medical Going Private In $1.3B Deal Led By 3 Firms
American Industrial Partners has agreed to acquire Avanos Medical Inc. in an all-cash transaction valued at nearly $1.3 billion, a take-private deal steered by three law firms, Avanos announced Tuesday.
-
April 14, 2026
State AGs, Albertsons Chain Reach $773M Opioid Deal
Albertsons Cos. Inc. and the attorneys general of California, Colorado, Illinois and Oregon on Tuesday said that the pharmacy and grocery chain had agreed to a $773 million settlement in principle to end claims brought by states, local governments and Native American tribes over its role in the opioid crisis.
-
April 14, 2026
Omnicare OK'd For Ch. 11 Auction With $250M Base Bid
Pharmacy services provider Omnicare's choice of a $250 million stalking horse bid for its assets was approved Tuesday by a Texas bankruptcy judge, setting up a possible auction in May.
-
April 13, 2026
Oracle Wins TRO Against Ex-Worker Threatening Secrets Sale
A North Carolina federal judge Monday issued a temporary restraining order barring a recently laid-off Oracle sales employee from disclosing trade secrets that the software firm alleges he has threatened to sell to the "highest bidder" unless he receives an "unreasonable" fee.
-
April 13, 2026
Citron's 'Shadowy Gang' Sued Over Short Selling Campaign
Shareholders of PolarityTE have alleged in a new suit that "members of a shadowy gang of short sellers" conspired to short the biotechnology company's stock through targeted negative media attacks with Citron Research to enrich themselves at the expense of the shareholders, and that they ultimately caused the company's bankruptcy.
-
April 13, 2026
Ill. Judge Wants More Proof To Recalculate Kickback Damages
An Illinois federal judge tasked with recalculating damages from a home health company's referral kickback scheme said Monday that she needs more complete and reliable evidence to help determine the appropriate amount, but allowed the government to continue offsetting Medicare payments as part of its judgment collection bid.
-
April 13, 2026
FTC Ends Teen Height Growth Supplement Claims
A supplement maker and its owners agreed to pay $750,000 to end claims they misled customers into thinking their products could make their children taller, the Federal Trade Commission announced on Monday.
-
April 13, 2026
Del. Judge Ends 80K Pre-2026 Zantac Cases
A Delaware state court on Monday dismissed more than 80,000 suits filed before December alleging that Boehringer Ingelheim's discontinued heartburn medication Zantac caused cancer, following a Delaware Supreme Court ruling on admissibility of the plaintiffs' experts.
-
April 13, 2026
Obesity Drugmaker Leads 2 Biotech Startups Eyeing IPOs
Two biotechnology startup companies on Monday filed plans for their public debuts, with obesity-focused Kailera Therapeutics planning to raise an estimated $500 million in its initial public offering and protein biomarker detection platform Alamar Biosciences planning to raise around $150 million.
-
April 13, 2026
Mylan Can't Revive Copaxone Antitrust Claims Against Teva
A New Jersey federal judge sided Monday with a special master's recommendations to nix some of the parallel claims from Mylan and retailers like Walgreens accusing Teva of using regulatory deception, false advertising, improper rebates and more to delay generic competition to its Copaxone multiple sclerosis treatment.
-
April 13, 2026
Hikma Tells Justices Cox Ruling Boosts 'Skinny Label' Case
Hikma Pharmaceuticals USA Inc. told the U.S. Supreme Court on Monday that the justices' recent decision clearing an internet company in a copyright case bolsters the drugmaker's challenge to a patent suit over its generic version of an Amarin Pharma Inc. heart drug.
-
April 13, 2026
VC Apple Tree Seeks $7M As Judge Mulls Ch. 11 Funding Fight
Biotech investor Apple Tree Life Sciences Inc. asked a Delaware bankruptcy judge to let it use $7 million from a larger funding motion she has yet to rule on, saying it needs the money for operating expenses and drug development costs.
-
April 13, 2026
AI Cardiac Imaging Co. Hits Ex-Consultant With IP Suit
Artificial intelligence-powered cardiac imaging company Heartflow Inc. filed patent infringement and trade secret misappropriation claims on Monday against a competitor founded by a former consultant who, the company says, lifted technological trade secrets while he was under contract.
Expert Analysis
-
Moderna Case Highlights Overlooked Hurdle In Biopharma IP
The recent settlement of the patent litigation involving Moderna's COVID-19 vaccine in Delaware federal court shows that patent portfolios covering enabling platform technologies can create significant freedom-to-operate risk even when their owners are not direct competitors developing the therapeutic product, says Olga Berson at Thompson Coburn.
-
FDA Framework For Personalized Therapies Raises Questions
The U.S. Food and Drug Administration's new plausible mechanism framework for developing individualized therapies reflects the agency's focus on rare-disease drugs, but numerous significant, unresolved issues cast uncertainty on how effective the framework will be in practice, say attorneys at Ropes & Gray.
-
Emissions Permits May Not Override Pollution Exclusions
Two recent coverage rulings from the Illinois Supreme Court and the Third Circuit suggest a trend among appellate courts to deny coverage under pollution exclusions, even when the emissions happened pursuant to a government permit, say attorneys at Simpson Thacher.
-
5 Tips For Navigating Your Firm's All-Attorney Summit
Excerpt from Practical Guidance
Law firm retreats should be approached strategically, as they present valuable opportunities to advance both the firm's objectives and attorneys' professional development through meaningful participation, building and strengthening internal relationships, and proactive follow-up, says James Argionis at Cozen O’Connor.
-
Series
Coaching Soccer Makes Me A Better Lawyer
Coaching youth soccer for my 7-year-old son's team has sharpened how I communicate with clients, prepare witnesses, work within teams and think about leadership, making me a more thoughtful and effective lawyer in many ways, says Joshua Holt at Smith Currie.
-
Series
Law School's Missed Lessons: The Human Element
Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.
-
Avoid The Unexpected When Drafting License Agreements
The Delaware Court of Chancery's recent decision in Commave v. Zevrain raises several practice points for attorneys drafting commercial contracts, underscoring the importance of considering anti-assignment provisions, specific exclusions and potential carveouts when drafting license agreements or other commercial contracts, say attorneys at Hogan Lovells.
-
CMS Healthcare Enforcement Initiatives May Cause Disruption
The Centers for Medicare & Medicaid Services' recently announced enforcement actions against healthcare fraud mark a significant escalation, and CMS' prior approach in the hospice sector suggests that even compliant providers and suppliers should brace for impact, say attorneys at Morgan Lewis.
-
The Benefits Of Choosing A Niche Practice In The AI Age
As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.
-
How PBMs Can Adapt To Plan Sponsors' Disclosure Demands
As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.
-
What New Animal Welfare Enforcement Push Means For Cos.
The Trump administration's recently announced multiagency focus on violations of the Animal Welfare Act and related laws will likely lead to broader enforcement actions across industries, heightened scrutiny of compliance standards and a need for businesses to adopt effective risk management practices, says Shennie Patel at Crowell & Moring.
-
How To Engage With Gov't's Direct-To-Consumer Drug Policy
The U.S. Department of Health and Human Services' recent request for industry input on manufacturers' direct-to-consumer drug sales reflects the government's caution in this arena, and allows stakeholders a rare opportunity to help shape policy, says Mary Kohler at Kohler Health Law.
-
Series
Podcasting Makes Me A Better Lawyer
Podcasting has changed how I ask questions and connect with people, sharpening my ability to listen without interrupting or prejudging, and bringing me closer to what law is meant to be: a human profession grounded in understanding, judgment and trust, says Donna DiMaggio Berger at Becker.
-
Patent Eligibility Bulletin: Steps To Consider As USPTO Shifts
Recent memoranda from the U.S. Patent and Trademark Office, along with some of the first patents issued under Director John Squires, indicate a recalibration of the subject matter eligibility landscape, signaling a renewed emphasis on concrete technological improvements and a potentially pro-AI stance, say attorneys at Banner Witcoff.
-
Tax Court Ruling Signals Cross-Border Loan Scrutiny
The U.S. Tax Court’s recent decision in Aventis v. Commissioner compounds ongoing regulatory focus on debt originations and should prompt practitioners to assess their existing cross-border lending structures for potential exposure to U.S. federal income tax, say attorneys at Eversheds.